JavaScript is NOT enabled !

Please enable JavaScript.

Article

PubMed

This record comes from PubMed

Prevention of Stroke with Ticagrelor in Patients with Prior Myocardial Infarction: Insights from PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54)

Bonaca, Marc P
Author Bonaca, Marc P From TIMI Study Group, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (M.P.B., D.L.B., E.G., D.A.M., E.B., M.S.); Tokai University School of Medicine; Institute of Medical Science, Isehara, Japan (S.G.); FACT, DHU-FIRE INSERM Unité 1148, Assistance Publique-Hôpitaux de Paris and Université Paris Diderot, Paris, France, and NHLI Imperial College, Royal Brompton Hospital, London, UK (P.G.S.); University of Sheffield, United Kingdom (R.F.S.); Division of Cardiology, Newark Beth Israel Medical Center, Rutgers-New Jersey Medical School, Newark (M.C.); Brigham and Women's Hospital and Harvard Clinical Research Institute, Harvard Medical School, Boston, MA (L.M.); CWZ Hospital, Nijmegen, The Netherlands (T.O.O.); Cardiology Research and Production complex MH RF, Moscow, Russia (M.R.); Internal Cardiology Department, University Hospital and Medical faculty, Brno, Czech Republic (J.S.); Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea (K.-B.S.); Heart Institute, Intervention Center, People Hospital of Peking University, China (D.H.); Life Fourways Hospital, Randburg, South Africa (A.J.D.); and AstraZeneca, Mölndal, Sweden (E.J., P.H.). mbonaca@partners.org
Goto, Shinya
Author Goto, Shinya From TIMI Study Group, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (M.P.B., D.L.B., E.G., D.A.M., E.B., M.S.); Tokai University School of Medicine; Institute of Medical Science, Isehara, Japan (S.G.); FACT, DHU-FIRE INSERM Unité 1148, Assistance Publique-Hôpitaux de Paris and Université Paris Diderot, Paris, France, and NHLI Imperial College, Royal Brompton Hospital, London, UK (P.G.S.); University of Sheffield, United Kingdom (R.F.S.); Division of Cardiology, Newark Beth Israel Medical Center, Rutgers-New Jersey Medical School, Newark (M.C.); Brigham and Women's Hospital and Harvard Clinical Research Institute, Harvard Medical School, Boston, MA (L.M.); CWZ Hospital, Nijmegen, The Netherlands (T.O.O.); Cardiology Research and Production complex MH RF, Moscow, Russia (M.R.); Internal Cardiology Department, University Hospital and Medical faculty, Brno, Czech Republic (J.S.); Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea (K.-B.S.); Heart Institute, Intervention Center, People Hospital of Peking University, China (D.H.); Life Fourways Hospital, Randburg, South Africa (A.J.D.); and AstraZeneca, Mölndal, Sweden (E.J., P.H.)
Bhatt, Deepak L
Author Bhatt, Deepak L From TIMI Study Group, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (M.P.B., D.L.B., E.G., D.A.M., E.B., M.S.); Tokai University School of Medicine; Institute of Medical Science, Isehara, Japan (S.G.); FACT, DHU-FIRE INSERM Unité 1148, Assistance Publique-Hôpitaux de Paris and Université Paris Diderot, Paris, France, and NHLI Imperial College, Royal Brompton Hospital, London, UK (P.G.S.); University of Sheffield, United Kingdom (R.F.S.); Division of Cardiology, Newark Beth Israel Medical Center, Rutgers-New Jersey Medical School, Newark (M.C.); Brigham and Women's Hospital and Harvard Clinical Research Institute, Harvard Medical School, Boston, MA (L.M.); CWZ Hospital, Nijmegen, The Netherlands (T.O.O.); Cardiology Research and Production complex MH RF, Moscow, Russia (M.R.); Internal Cardiology Department, University Hospital and Medical faculty, Brno, Czech Republic (J.S.); Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea (K.-B.S.); Heart Institute, Intervention Center, People Hospital of Peking University, China (D.H.); Life Fourways Hospital, Randburg, South Africa (A.J.D.); and AstraZeneca, Mölndal, Sweden (E.J., P.H.)
Steg, P Gabriel
Author Steg, P Gabriel From TIMI Study Group, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (M.P.B., D.L.B., E.G., D.A.M., E.B., M.S.); Tokai University School of Medicine; Institute of Medical Science, Isehara, Japan (S.G.); FACT, DHU-FIRE INSERM Unité 1148, Assistance Publique-Hôpitaux de Paris and Université Paris Diderot, Paris, France, and NHLI Imperial College, Royal Brompton Hospital, London, UK (P.G.S.); University of Sheffield, United Kingdom (R.F.S.); Division of Cardiology, Newark Beth Israel Medical Center, Rutgers-New Jersey Medical School, Newark (M.C.); Brigham and Women's Hospital and Harvard Clinical Research Institute, Harvard Medical School, Boston, MA (L.M.); CWZ Hospital, Nijmegen, The Netherlands (T.O.O.); Cardiology Research and Production complex MH RF, Moscow, Russia (M.R.); Internal Cardiology Department, University Hospital and Medical faculty, Brno, Czech Republic (J.S.); Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea (K.-B.S.); Heart Institute, Intervention Center, People Hospital of Peking University, China (D.H.); Life Fourways Hospital, Randburg, South Africa (A.J.D.); and AstraZeneca, Mölndal, Sweden (E.J., P.H.)
Storey, Robert F
Author Storey, Robert F From TIMI Study Group, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (M.P.B., D.L.B., E.G., D.A.M., E.B., M.S.); Tokai University School of Medicine; Institute of Medical Science, Isehara, Japan (S.G.); FACT, DHU-FIRE INSERM Unité 1148, Assistance Publique-Hôpitaux de Paris and Université Paris Diderot, Paris, France, and NHLI Imperial College, Royal Brompton Hospital, London, UK (P.G.S.); University of Sheffield, United Kingdom (R.F.S.); Division of Cardiology, Newark Beth Israel Medical Center, Rutgers-New Jersey Medical School, Newark (M.C.); Brigham and Women's Hospital and Harvard Clinical Research Institute, Harvard Medical School, Boston, MA (L.M.); CWZ Hospital, Nijmegen, The Netherlands (T.O.O.); Cardiology Research and Production complex MH RF, Moscow, Russia (M.R.); Internal Cardiology Department, University Hospital and Medical faculty, Brno, Czech Republic (J.S.); Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea (K.-B.S.); Heart Institute, Intervention Center, People Hospital of Peking University, China (D.H.); Life Fourways Hospital, Randburg, South Africa (A.J.D.); and AstraZeneca, Mölndal, Sweden (E.J., P.H.)
Cohen, Marc
Author Cohen, Marc From TIMI Study Group, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (M.P.B., D.L.B., E.G., D.A.M., E.B., M.S.); Tokai University School of Medicine; Institute of Medical Science, Isehara, Japan (S.G.); FACT, DHU-FIRE INSERM Unité 1148, Assistance Publique-Hôpitaux de Paris and Université Paris Diderot, Paris, France, and NHLI Imperial College, Royal Brompton Hospital, London, UK (P.G.S.); University of Sheffield, United Kingdom (R.F.S.); Division of Cardiology, Newark Beth Israel Medical Center, Rutgers-New Jersey Medical School, Newark (M.C.); Brigham and Women's Hospital and Harvard Clinical Research Institute, Harvard Medical School, Boston, MA (L.M.); CWZ Hospital, Nijmegen, The Netherlands (T.O.O.); Cardiology Research and Production complex MH RF, Moscow, Russia (M.R.); Internal Cardiology Department, University Hospital and Medical faculty, Brno, Czech Republic (J.S.); Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea (K.-B.S.); Heart Institute, Intervention Center, People Hospital of Peking University, China (D.H.); Life Fourways Hospital, Randburg, South Africa (A.J.D.); and AstraZeneca, Mölndal, Sweden (E.J., P.H.)
Goodrich, Erica
Author Goodrich, Erica From TIMI Study Group, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (M.P.B., D.L.B., E.G., D.A.M., E.B., M.S.); Tokai University School of Medicine; Institute of Medical Science, Isehara, Japan (S.G.); FACT, DHU-FIRE INSERM Unité 1148, Assistance Publique-Hôpitaux de Paris and Université Paris Diderot, Paris, France, and NHLI Imperial College, Royal Brompton Hospital, London, UK (P.G.S.); University of Sheffield, United Kingdom (R.F.S.); Division of Cardiology, Newark Beth Israel Medical Center, Rutgers-New Jersey Medical School, Newark (M.C.); Brigham and Women's Hospital and Harvard Clinical Research Institute, Harvard Medical School, Boston, MA (L.M.); CWZ Hospital, Nijmegen, The Netherlands (T.O.O.); Cardiology Research and Production complex MH RF, Moscow, Russia (M.R.); Internal Cardiology Department, University Hospital and Medical faculty, Brno, Czech Republic (J.S.); Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea (K.-B.S.); Heart Institute, Intervention Center, People Hospital of Peking University, China (D.H.); Life Fourways Hospital, Randburg, South Africa (A.J.D.); and AstraZeneca, Mölndal, Sweden (E.J., P.H.)
Mauri, Laura
Author Mauri, Laura From TIMI Study Group, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (M.P.B., D.L.B., E.G., D.A.M., E.B., M.S.); Tokai University School of Medicine; Institute of Medical Science, Isehara, Japan (S.G.); FACT, DHU-FIRE INSERM Unité 1148, Assistance Publique-Hôpitaux de Paris and Université Paris Diderot, Paris, France, and NHLI Imperial College, Royal Brompton Hospital, London, UK (P.G.S.); University of Sheffield, United Kingdom (R.F.S.); Division of Cardiology, Newark Beth Israel Medical Center, Rutgers-New Jersey Medical School, Newark (M.C.); Brigham and Women's Hospital and Harvard Clinical Research Institute, Harvard Medical School, Boston, MA (L.M.); CWZ Hospital, Nijmegen, The Netherlands (T.O.O.); Cardiology Research and Production complex MH RF, Moscow, Russia (M.R.); Internal Cardiology Department, University Hospital and Medical faculty, Brno, Czech Republic (J.S.); Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea (K.-B.S.); Heart Institute, Intervention Center, People Hospital of Peking University, China (D.H.); Life Fourways Hospital, Randburg, South Africa (A.J.D.); and AstraZeneca, Mölndal, Sweden (E.J., P.H.)
Ophuis, Ton Oude
Author Ophuis, Ton Oude From TIMI Study Group, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (M.P.B., D.L.B., E.G., D.A.M., E.B., M.S.); Tokai University School of Medicine; Institute of Medical Science, Isehara, Japan (S.G.); FACT, DHU-FIRE INSERM Unité 1148, Assistance Publique-Hôpitaux de Paris and Université Paris Diderot, Paris, France, and NHLI Imperial College, Royal Brompton Hospital, London, UK (P.G.S.); University of Sheffield, United Kingdom (R.F.S.); Division of Cardiology, Newark Beth Israel Medical Center, Rutgers-New Jersey Medical School, Newark (M.C.); Brigham and Women's Hospital and Harvard Clinical Research Institute, Harvard Medical School, Boston, MA (L.M.); CWZ Hospital, Nijmegen, The Netherlands (T.O.O.); Cardiology Research and Production complex MH RF, Moscow, Russia (M.R.); Internal Cardiology Department, University Hospital and Medical faculty, Brno, Czech Republic (J.S.); Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea (K.-B.S.); Heart Institute, Intervention Center, People Hospital of Peking University, China (D.H.); Life Fourways Hospital, Randburg, South Africa (A.J.D.); and AstraZeneca, Mölndal, Sweden (E.J., P.H.)
Ruda, Mikhail
Author Ruda, Mikhail From TIMI Study Group, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (M.P.B., D.L.B., E.G., D.A.M., E.B., M.S.); Tokai University School of Medicine; Institute of Medical Science, Isehara, Japan (S.G.); FACT, DHU-FIRE INSERM Unité 1148, Assistance Publique-Hôpitaux de Paris and Université Paris Diderot, Paris, France, and NHLI Imperial College, Royal Brompton Hospital, London, UK (P.G.S.); University of Sheffield, United Kingdom (R.F.S.); Division of Cardiology, Newark Beth Israel Medical Center, Rutgers-New Jersey Medical School, Newark (M.C.); Brigham and Women's Hospital and Harvard Clinical Research Institute, Harvard Medical School, Boston, MA (L.M.); CWZ Hospital, Nijmegen, The Netherlands (T.O.O.); Cardiology Research and Production complex MH RF, Moscow, Russia (M.R.); Internal Cardiology Department, University Hospital and Medical faculty, Brno, Czech Republic (J.S.); Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea (K.-B.S.); Heart Institute, Intervention Center, People Hospital of Peking University, China (D.H.); Life Fourways Hospital, Randburg, South Africa (A.J.D.); and AstraZeneca, Mölndal, Sweden (E.J., P.H.)
Špinar, Jindřich
Author Špinar, Jindřich From TIMI Study Group, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (M.P.B., D.L.B., E.G., D.A.M., E.B., M.S.); Tokai University School of Medicine; Institute of Medical Science, Isehara, Japan (S.G.); FACT, DHU-FIRE INSERM Unité 1148, Assistance Publique-Hôpitaux de Paris and Université Paris Diderot, Paris, France, and NHLI Imperial College, Royal Brompton Hospital, London, UK (P.G.S.); University of Sheffield, United Kingdom (R.F.S.); Division of Cardiology, Newark Beth Israel Medical Center, Rutgers-New Jersey Medical School, Newark (M.C.); Brigham and Women's Hospital and Harvard Clinical Research Institute, Harvard Medical School, Boston, MA (L.M.); CWZ Hospital, Nijmegen, The Netherlands (T.O.O.); Cardiology Research and Production complex MH RF, Moscow, Russia (M.R.); Internal Cardiology Department, University Hospital and Medical faculty, Brno, Czech Republic (J.S.); Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea (K.-B.S.); Heart Institute, Intervention Center, People Hospital of Peking University, China (D.H.); Life Fourways Hospital, Randburg, South Africa (A.J.D.); and AstraZeneca, Mölndal, Sweden (E.J., P.H.)
Seung, Ki-Bae
Author Seung, Ki-Bae From TIMI Study Group, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (M.P.B., D.L.B., E.G., D.A.M., E.B., M.S.); Tokai University School of Medicine; Institute of Medical Science, Isehara, Japan (S.G.); FACT, DHU-FIRE INSERM Unité 1148, Assistance Publique-Hôpitaux de Paris and Université Paris Diderot, Paris, France, and NHLI Imperial College, Royal Brompton Hospital, London, UK (P.G.S.); University of Sheffield, United Kingdom (R.F.S.); Division of Cardiology, Newark Beth Israel Medical Center, Rutgers-New Jersey Medical School, Newark (M.C.); Brigham and Women's Hospital and Harvard Clinical Research Institute, Harvard Medical School, Boston, MA (L.M.); CWZ Hospital, Nijmegen, The Netherlands (T.O.O.); Cardiology Research and Production complex MH RF, Moscow, Russia (M.R.); Internal Cardiology Department, University Hospital and Medical faculty, Brno, Czech Republic (J.S.); Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea (K.-B.S.); Heart Institute, Intervention Center, People Hospital of Peking University, China (D.H.); Life Fourways Hospital, Randburg, South Africa (A.J.D.); and AstraZeneca, Mölndal, Sweden (E.J., P.H.)
Hu, Dayi
Author Hu, Dayi From TIMI Study Group, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (M.P.B., D.L.B., E.G., D.A.M., E.B., M.S.); Tokai University School of Medicine; Institute of Medical Science, Isehara, Japan (S.G.); FACT, DHU-FIRE INSERM Unité 1148, Assistance Publique-Hôpitaux de Paris and Université Paris Diderot, Paris, France, and NHLI Imperial College, Royal Brompton Hospital, London, UK (P.G.S.); University of Sheffield, United Kingdom (R.F.S.); Division of Cardiology, Newark Beth Israel Medical Center, Rutgers-New Jersey Medical School, Newark (M.C.); Brigham and Women's Hospital and Harvard Clinical Research Institute, Harvard Medical School, Boston, MA (L.M.); CWZ Hospital, Nijmegen, The Netherlands (T.O.O.); Cardiology Research and Production complex MH RF, Moscow, Russia (M.R.); Internal Cardiology Department, University Hospital and Medical faculty, Brno, Czech Republic (J.S.); Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea (K.-B.S.); Heart Institute, Intervention Center, People Hospital of Peking University, China (D.H.); Life Fourways Hospital, Randburg, South Africa (A.J.D.); and AstraZeneca, Mölndal, Sweden (E.J., P.H.)
Dalby, Anthony J
Author Dalby, Anthony J From TIMI Study Group, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (M.P.B., D.L.B., E.G., D.A.M., E.B., M.S.); Tokai University School of Medicine; Institute of Medical Science, Isehara, Japan (S.G.); FACT, DHU-FIRE INSERM Unité 1148, Assistance Publique-Hôpitaux de Paris and Université Paris Diderot, Paris, France, and NHLI Imperial College, Royal Brompton Hospital, London, UK (P.G.S.); University of Sheffield, United Kingdom (R.F.S.); Division of Cardiology, Newark Beth Israel Medical Center, Rutgers-New Jersey Medical School, Newark (M.C.); Brigham and Women's Hospital and Harvard Clinical Research Institute, Harvard Medical School, Boston, MA (L.M.); CWZ Hospital, Nijmegen, The Netherlands (T.O.O.); Cardiology Research and Production complex MH RF, Moscow, Russia (M.R.); Internal Cardiology Department, University Hospital and Medical faculty, Brno, Czech Republic (J.S.); Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea (K.-B.S.); Heart Institute, Intervention Center, People Hospital of Peking University, China (D.H.); Life Fourways Hospital, Randburg, South Africa (A.J.D.); and AstraZeneca, Mölndal, Sweden (E.J., P.H.)
Jensen, Eva
Author Jensen, Eva From TIMI Study Group, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (M.P.B., D.L.B., E.G., D.A.M., E.B., M.S.); Tokai University School of Medicine; Institute of Medical Science, Isehara, Japan (S.G.); FACT, DHU-FIRE INSERM Unité 1148, Assistance Publique-Hôpitaux de Paris and Université Paris Diderot, Paris, France, and NHLI Imperial College, Royal Brompton Hospital, London, UK (P.G.S.); University of Sheffield, United Kingdom (R.F.S.); Division of Cardiology, Newark Beth Israel Medical Center, Rutgers-New Jersey Medical School, Newark (M.C.); Brigham and Women's Hospital and Harvard Clinical Research Institute, Harvard Medical School, Boston, MA (L.M.); CWZ Hospital, Nijmegen, The Netherlands (T.O.O.); Cardiology Research and Production complex MH RF, Moscow, Russia (M.R.); Internal Cardiology Department, University Hospital and Medical faculty, Brno, Czech Republic (J.S.); Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea (K.-B.S.); Heart Institute, Intervention Center, People Hospital of Peking University, China (D.H.); Life Fourways Hospital, Randburg, South Africa (A.J.D.); and AstraZeneca, Mölndal, Sweden (E.J., P.H.)
Held, Peter
Author Held, Peter From TIMI Study Group, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (M.P.B., D.L.B., E.G., D.A.M., E.B., M.S.); Tokai University School of Medicine; Institute of Medical Science, Isehara, Japan (S.G.); FACT, DHU-FIRE INSERM Unité 1148, Assistance Publique-Hôpitaux de Paris and Université Paris Diderot, Paris, France, and NHLI Imperial College, Royal Brompton Hospital, London, UK (P.G.S.); University of Sheffield, United Kingdom (R.F.S.); Division of Cardiology, Newark Beth Israel Medical Center, Rutgers-New Jersey Medical School, Newark (M.C.); Brigham and Women's Hospital and Harvard Clinical Research Institute, Harvard Medical School, Boston, MA (L.M.); CWZ Hospital, Nijmegen, The Netherlands (T.O.O.); Cardiology Research and Production complex MH RF, Moscow, Russia (M.R.); Internal Cardiology Department, University Hospital and Medical faculty, Brno, Czech Republic (J.S.); Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea (K.-B.S.); Heart Institute, Intervention Center, People Hospital of Peking University, China (D.H.); Life Fourways Hospital, Randburg, South Africa (A.J.D.); and AstraZeneca, Mölndal, Sweden (E.J., P.H.)
Morrow, David A
Author Morrow, David A From TIMI Study Group, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (M.P.B., D.L.B., E.G., D.A.M., E.B., M.S.); Tokai University School of Medicine; Institute of Medical Science, Isehara, Japan (S.G.); FACT, DHU-FIRE INSERM Unité 1148, Assistance Publique-Hôpitaux de Paris and Université Paris Diderot, Paris, France, and NHLI Imperial College, Royal Brompton Hospital, London, UK (P.G.S.); University of Sheffield, United Kingdom (R.F.S.); Division of Cardiology, Newark Beth Israel Medical Center, Rutgers-New Jersey Medical School, Newark (M.C.); Brigham and Women's Hospital and Harvard Clinical Research Institute, Harvard Medical School, Boston, MA (L.M.); CWZ Hospital, Nijmegen, The Netherlands (T.O.O.); Cardiology Research and Production complex MH RF, Moscow, Russia (M.R.); Internal Cardiology Department, University Hospital and Medical faculty, Brno, Czech Republic (J.S.); Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea (K.-B.S.); Heart Institute, Intervention Center, People Hospital of Peking University, China (D.H.); Life Fourways Hospital, Randburg, South Africa (A.J.D.); and AstraZeneca, Mölndal, Sweden (E.J., P.H.)
Braunwald, Eugene
Author Braunwald, Eugene From TIMI Study Group, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (M.P.B., D.L.B., E.G., D.A.M., E.B., M.S.); Tokai University School of Medicine; Institute of Medical Science, Isehara, Japan (S.G.); FACT, DHU-FIRE INSERM Unité 1148, Assistance Publique-Hôpitaux de Paris and Université Paris Diderot, Paris, France, and NHLI Imperial College, Royal Brompton Hospital, London, UK (P.G.S.); University of Sheffield, United Kingdom (R.F.S.); Division of Cardiology, Newark Beth Israel Medical Center, Rutgers-New Jersey Medical School, Newark (M.C.); Brigham and Women's Hospital and Harvard Clinical Research Institute, Harvard Medical School, Boston, MA (L.M.); CWZ Hospital, Nijmegen, The Netherlands (T.O.O.); Cardiology Research and Production complex MH RF, Moscow, Russia (M.R.); Internal Cardiology Department, University Hospital and Medical faculty, Brno, Czech Republic (J.S.); Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea (K.-B.S.); Heart Institute, Intervention Center, People Hospital of Peking University, China (D.H.); Life Fourways Hospital, Randburg, South Africa (A.J.D.); and AstraZeneca, Mölndal, Sweden (E.J., P.H.)
Sabatine, Marc S
Author Sabatine, Marc S From TIMI Study Group, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (M.P.B., D.L.B., E.G., D.A.M., E.B., M.S.); Tokai University School of Medicine; Institute of Medical Science, Isehara, Japan (S.G.); FACT, DHU-FIRE INSERM Unité 1148, Assistance Publique-Hôpitaux de Paris and Université Paris Diderot, Paris, France, and NHLI Imperial College, Royal Brompton Hospital, London, UK (P.G.S.); University of Sheffield, United Kingdom (R.F.S.); Division of Cardiology, Newark Beth Israel Medical Center, Rutgers-New Jersey Medical School, Newark (M.C.); Brigham and Women's Hospital and Harvard Clinical Research Institute, Harvard Medical School, Boston, MA (L.M.); CWZ Hospital, Nijmegen, The Netherlands (T.O.O.); Cardiology Research and Production complex MH RF, Moscow, Russia (M.R.); Internal Cardiology Department, University Hospital and Medical faculty, Brno, Czech Republic (J.S.); Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea (K.-B.S.); Heart Institute, Intervention Center, People Hospital of Peking University, China (D.H.); Life Fourways Hospital, Randburg, South Africa (A.J.D.); and AstraZeneca, Mölndal, Sweden (E.J., P.H.)

Circulation. 2016 Sep 20 ; 134 (12) : 861-71. [epub] 20160830

ISSN 1524-4539 | 0009-7322
Source

Language English Country United States Media print-electronic

Document type Journal Article, Randomized Controlled Trial

Persistent link https://www.medvik.cz/link/pmid27576775

PubMed 27576775
DOI 10.1161/circulationaha.116.024637
PII: CIRCULATIONAHA.116.024637
Knihovny.cz E-resources

Keywords
hemorrhagic stroke, ischemic stroke, platelet aggregation inhibitors, secondary prevention, stroke, thrombosis, ticagrelor,
MeSH
Adenosine administration & dosage analogs & derivatives therapeutic use MeSH
Purinergic P2Y Receptor Antagonists therapeutic use MeSH
Aspirin administration & dosage therapeutic use MeSH
Stroke drug therapy prevention & control MeSH
Myocardial Infarction drug therapy prevention & control MeSH
Platelet Aggregation Inhibitors therapeutic use MeSH
Intracranial Hemorrhages prevention & control MeSH
Hemorrhage chemically induced MeSH
Middle Aged MeSH
Humans MeSH
Coronary Artery Disease drug therapy MeSH
Risk MeSH
Secondary Prevention methods MeSH
Aged MeSH
Ticagrelor MeSH
Check Tag
Middle Aged MeSH
Humans MeSH
Male MeSH
Aged MeSH
Female MeSH
Publication type
Journal Article MeSH
Randomized Controlled Trial MeSH
Names of Substances
Adenosine MeSH
Purinergic P2Y Receptor Antagonists MeSH
Aspirin MeSH
Platelet Aggregation Inhibitors MeSH
Ticagrelor MeSH

BACKGROUND: In the PEGASUS-TIMI 54 trial (Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54), ticagrelor reduced the risk of major adverse cardiovascular events when added to low-dose aspirin in stable patients with prior myocardial infarction, resulting in the approval of ticagrelor 60 mg twice daily for long-term secondary prevention. We investigated the incidence of stroke, outcomes after stroke, and the efficacy of ticagrelor focusing on the approved 60 mg twice daily dose for reducing stroke in this population. METHODS: Patients were followed for a median of 33 months. Stroke events were adjudicated by a central committee. Data from similar trials were combined using meta-analysis. RESULTS: Of 14 112 patients randomly assigned to placebo or ticagrelor 60 mg, 213 experienced a stroke; 85% of these strokes were ischemic. A total of 18% of strokes were fatal and another 15% led to either moderate or severe disability at 30 days. Ticagrelor significantly reduced the risk of stroke (hazard ratio, 0.75; 95% confidence interval, 0.57-0.98; P=0.034), driven by a reduction in ischemic stroke (hazard ratio, 0.76; 95% confidence interval, 0.56-1.02). Hemorrhagic stroke occurred in 9 patients on placebo and 8 patients on ticagrelor. A meta-analysis across 4 placebo-controlled trials of more intensive antiplatelet therapy in 44 816 patients with coronary disease confirmed a marked reduction in ischemic stroke (hazard ratio, 0.66; 95% confidence interval, 0.54-0.81; P=0.0001). CONCLUSIONS: High-risk patients with prior myocardial infarction are at risk for stroke, approximately one-third of which are fatal or lead to moderate-to-severe disability. The addition of ticagrelor 60 mg twice daily significantly reduced this risk without an excess of hemorrhagic stroke but with more major bleeding. In high-risk patients with coronary disease, more intensive antiplatelet therapy should be considered not only to reduce the risk of coronary events, but also of stroke. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique Identifier: NCT01225562.

From TIMI Study Group Brigham and Women's Hospital Harvard Medical School Boston MA

References provided by Crossref.org

Newest 20 citations...

See more in
Medvik | PubMed

Cardiovascular care of patients with stroke and high risk of stroke: The need for interdisciplinary action: A consensus report from the European Society of Cardiology Cardiovascular Round Table

European journal of preventive cardiology. 2020 May ; 27 (7) : 682-692. [epub] 20190930

Eur J Prev Cardiol
ISSN 2047-4881 | 2047-4873
Source

See more in PubMed

ClinicalTrials.gov
NCT01225562

Borrow
RIS

Find record

In BMC

Prevention of Stroke with Ticagrelor in Patients with Prior Myocardial Infarction: Insights from PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54)

Find record

Citation metrics

Archiving options